Technology · Health & biomedicine / Therapeutics & platforms

Plasma-derived therapy manufacturing

Medicines made from donated human plasma — collection, screening, fractionation, purification and fill-finish — a commercial-scale industry with a reported 20 % CAGR in immunoglobulins, partly displaced by recombinant products for coagulation factors.

Maturity 9/9 Risk: medium Pharma & biologics Biomanufacturing & Bio-industrial Production US · EU · CN verified 2026-10-16 · 5 Sources

1 · What it gives

Plasma-derived therapies are medicines made from human plasma collected through donation; plasma cannot be manufactured in a laboratory. The process runs from collection and testing through fractionation, purification, filling and packaging. The industry is at commercial scale, with major companies investing in infrastructure and capacity; the immunoglobulin market is reported at a 20 % CAGR. For coagulation factors, plasma-derived products are in some cases being replaced by recombinant alternatives.

2 · What it replaces 6

D1	Fermentation (stainless and single-use bioreactors, solid-state reactors) and downstream equipment (centrifuges, filtration, spray and fluid-bed drying, formulation) for local production of enzymes, microbial products and fermentation ingredients instead of chemical-synthesis plants and imports Replaces: Chemical-synthesis routes and imports for the products in FI-, FD-, I- and A-series articles (enzymes, organic acids, vitamins, microbial …	EAC
D1	Lower-toxicity textile dyeing and dye-effluent treatment with biological methods — bio-based indigo reduction and enzymatic indigo routes, microbial pigments, and biological decolorization of dye effluent — instead of sodium dithionite reduction, aniline-derived synthetic indigo and untreated/chemically treated dye effluent Replaces: Sodium dithionite (hydrosulfite) for indigo vat reduction, synthetic indigo made from aniline (traces of aniline in dyed denim), some azo …	CHEM
D1	Recovered phosphorus (struvite and other recovered phosphates from biological wastewater and digester streams) instead of fertilizer made from cadmium-bearing phosphate rock Replaces: A share of DAP/MAP/superphosphate made from mined phosphate rock; chemical P-removal with iron and aluminium salts at treatment plants …	AGROCHEM
D2	Dairy mastitis prevention with selective dry-cow therapy, internal teat sealants and bacteriocin (nisin) teat disinfection Replaces: Blanket dry-cow antibiotic therapy (all quarters, all cows: cloxacillin, cephalosporins incl. 3rd/4th generation, penicillin–aminoglycoside …	VET
D2	Refractory gold ore processing by bacterial biooxidation (BIOX® and similar tank bioleaching) — instead of roasting; with biological cyanide destruction of tailings water Replaces: Roasting of arsenopyrite/pyrite gold concentrates (emissions of SO2 and arsenic trioxide), partly pressure oxidation (energy-intensive); …	SERV
D0	Bacteriophage therapy for bacterial disease in fish and shrimp farming instead of medicated-feed antibiotics Replaces: Antibiotics in medicated feed and bath treatments - oxytetracycline, florfenicol, oxolinic acid, enrofloxacin, sulfonamide-trimethoprim …	VET

3 · How to implement 5 steps

1
Collection
Collect plasma from donors.
2
Testing and screening
Test and screen the plasma.
3
Fractionation
Separate the proteins by fractionation.
4
Purification
Purify the target proteins.
5
Fill and package
Fill and package the final product.

4 · Who delivers

Matched suppliers (matched automatically)

EGAVET	Egypt	Research / RTO	active
Abtec	India	Research / RTO	active
EcoFix Kenya Ltd (EFK)	Kenya	Producer	active
PT. Central Proteina Prima, Tbk	Indonesia	Producer	active
Aristogene Biosciences Pvt. Ltd.	India	Producer	active
BioHAYAT	Turkey	Research / RTO	active
EnviroWay BioScience Pvt Ltd	India	Services / consulting	active
NSL Sugars	India	Research / RTO	active
XIKE Enzymes	China	Research / RTO	active
Boehringer Ingelheim	Germany	Producer	active
Aleph Farms	Israel	Producer	active
Biomason	United States	Producer	active

Leading companies and institutes (from the brief)

Takeda is named as a prominent manufacturer and sourcer of plasma-derived therapies. Other plasma fractionators are matched by the portal under Pharma & biologics and Biomanufacturing.

5 · Rules & route to market

Route into Russia / EAEU: EAC · EAEU accredited bodies / Rosakkreditatsiya
declaration registered within 3 working days (testing extra); certification longer
Information, not legal advice — confirm the procedure for your product. (2026-10-06)

United States

Manufacturing is governed by national and regional regulators — the FDA in the US and the EMA in the EU.

European Union

Manufacturing is governed by the EMA at EU level together with national authorities; the sources do not name further EU instruments.

China

The sources reviewed on 2026-10-16 identified no China regulator or standard specific to this technology. Treat the route as case-by-case and ask for a check.

6 · Money: tenders & grants

Tender	Czechia – Immunosuppressive agents – Selektivní Imunosupresiva - Eculizumab IV. Institut klinické a experimentální medicíny · Czechia	Oct 20, 2026 4 days
Tender	Czechia – Immunosuppressive agents – Takrolimus 1x denně - LP ADVAGRAF Institut klinické a experimentální medicíny · Czechia	Oct 20, 2026 4 days
Tender	Netherlands – Influenza vaccines – Trivalent Influenza Vaccines 2026 Rijksinstituut voor Volksgezondheid en Milieu (RIVM), RIVM · Netherlands	Oct 19, 2026 3 days
Grant	Circular innovative advanced materials: facilitating the transition from design to markets (RIA) (Innovative … European Commission · EU	Feb 2, 2027 109 days
Grant	Continuing Human Enabling Enhancing Restoring and Sustaining Air Force -- Research Lab · United States	Aug 22, 2044 6520 days
Grant	Enhancing ecodesign and circularity of construction products European Commission · EU	Sep 22, 2027 341 days
Grant	First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based … National Institutes of Health · United States	Oct 15, 2027 364 days
Grant	Health of ecosystems and wild species, predictions and impacts on human health, in the face of existing and … European Commission · EU	Sep 22, 2027 341 days

7 · Tech stack & innovations

Main risks from the sources: the high cost of raw material and manufacturing, the need to ensure viral safety, and stringent regulatory hurdles for process changes.

Sources 5

Assets dam.takeda.com — assets-dam.takeda.com 2026-10-16
Doi.org — doi.org 2026-10-16
Aob.amegroups.org — aob.amegroups.org 2026-10-16
Aob.amegroups.org — aob.amegroups.org 2026-10-16
Sec.gov — www.sec.gov 2026-10-16